Avricore Health Reports Steep Revenue Decline and Going Concern Warning Amid Major Customer Loss
summarizeSummary
The company's financial results for the nine months ended September 30, 2025, show a drastic 85% year-over-year revenue decrease and a shift to a comprehensive loss of $916,042. This severe deterioration is primarily due to the conclusion of its agreement with Shoppers Drug Mart, a major customer. Management explicitly stated a "material uncertainty" about the company's ability to continue as a going concern, highlighting its historical operating losses and negative cash flows. While the company outlines a strategy to focus on the UK market and redeploy existing devices, the immediate financial challenges and the going concern warning present significant risks to investors.
check_boxKey Events
-
Going Concern Warning Issued
Management disclosed a material uncertainty regarding the company's ability to continue as a going concern, citing historical operating losses and negative cash flows.
-
Significant Revenue Decline
Revenue for the nine months ended September 30, 2025, plummeted 85% year-over-year to $500,433, primarily due to the expiration of a major customer agreement.
-
Shift to Comprehensive Loss
The company reported a comprehensive loss of $916,042 for the nine-month period, a significant reversal from income in the prior year.
-
Cash Flow Deterioration
Net cash used in operating activities resulted in a $600,111 decrease in cash and cash equivalents for the nine-month period.
auto_awesomeAnalysis
The company's financial results for the nine months ended September 30, 2025, show a drastic 85% year-over-year revenue decrease and a shift to a comprehensive loss of $916,042. This severe deterioration is primarily due to the conclusion of its agreement with Shoppers Drug Mart, a major customer. Management explicitly stated a "material uncertainty" about the company's ability to continue as a going concern, highlighting its historical operating losses and negative cash flows. While the company outlines a strategy to focus on the UK market and redeploy existing devices, the immediate financial challenges and the going concern warning present significant risks to investors.
在该文件披露时,AVCRF的交易价格为$0.04,交易所为OTC,所属行业为Life Sciences,市值约为$357万。 52周交易区间为$0.01至$0.25。 这份文件被评估为消极市场情绪,重要性评分为9/10。